The role of radiation treatment in the management of inflammatory musculoskeletal conditions: a revisit

Abstract

Disabilities as a result of musculoskeletal disorders increased by 45% from 1990 to 2010. Furthermore, OA is listed by the World Health Organization as the fastest increasing major health condition and ranked as the 2nd leading cause of disability [3]. OA is the underlying cause for more than 90% of the increasing number of total hip or knee joint replacement operations worldwide [4]. Studies from Africa show the prevalence of OA in South Africa is over 29.5% while that of Nigeria is 0.4% [5]. The Community Oriented Program for Control of Rheumatic Diseases (COPCORD) studies in Asia show the prevalence of OA is as high as 34% among people in the 60-64 years age bracket [6]. In the United States, the prevalence of OA increased from 6.6% in 1999 to 14.3% in 2014 [7]. However, in the same time-period, in the United States, the prevalence of rheumatoid arthritis (RA) reduced from 5.9% to 3.8% [7]. Rheumatoid arthritis is the 2nd highest attributable disease to global disability [8]. It has a twofold morbidity among women compared to men [9]. And it has been estimated that China had

Low Dose Radiation Therapy Induces Long-Lasting Reduction of Pain and Immune Modulations in the Peripheral Blood – Interim Analysis of the IMMO-LDRT01 Trial

“…LDRT is well known for its pain-relieving effects in chronic degenerative and inflammatory diseases ( 25 , 26 ). Indeed, the findings of the IMMO-LDRT01 trial strongly support this.…”

Treatment of benign tumours and related pathologies with radiotherapy: experience of the General Hospital of Mexico

“…Graves' ophthalmopathy was treated with doses of 20 Gy in 10 fractions; three of four patients received salvage RT, two were refractory to steroids, and one had already undergone decompressive surgery of the medial walls and floor of the orbit. The clinical effectiveness of RT in the management of degenerative pain disorders with a single dose of 0.3 to 0.7 Gy and a total dose of 3 to 10 Gy for pain relief is evident [4], as was observed in the patient with POEMS syndrome. There are pathologies that require higher doses in the range of 50 to 60 Gy in fractions of 1.8 to 2 Gy due to the characteristics of the pathology (e.g., paragangliomas, haemangiopericytomas, dermatofibromas and fibromatosis).…”

“…Graves’ ophthalmopathy was treated with doses of 20 Gy in 10 fractions; three of four patients received salvage RT, two were refractory to steroids, and one had already undergone decompressive surgery of the medial walls and floor of the orbit. The clinical effectiveness of RT in the management of degenerative pain disorders with a single dose of 0.3 to 0.7 Gy and a total dose of 3 to 10 Gy for pain relief is evident [ 4 ], as was observed in the patient with POEMS syndrome.…”

“…Twenty-five of 61 departments (41%) responded, reporting treatment of pathologies including heterotopic ossification, keloid scarring, Graves’ disease and Dupuytren’s disease, and trigeminal neuralgia and vestibular schwannoma were treated with radiosurgery [ 3 ]. The German RT Group for benign diseases, together with the German Society of Radiotherapy and Oncology (DEGRO), reviewed the experience from 1930 to 1990 and developed the first national guidelines for the use of RT for acute and chronic inflammatory diseases, degenerative joint disease and acute and chronic pain, with an update between 2010 and 2013 [ 4 , 5 ]. RT constitutes 8–10% of treatments used for benign pathology [ 6 , 7 ].…”

One-Week Dynamic Changes in Cardiac Proteomes After Cardiac Radioablation in Experimental Rat Model

“…Radiation therapy (RT) has been used for several non-malignant diseases such as degenerative arthritis or inflammatory diseases ( 1 ). Recently, cardiac radioablation using stereotactic ablative radiotherapy (SABR)/stereotactic body radiation therapy (SBRT) has been adopted to treat catheter ablation-refractory ventricular tachycardia (VT) by delivering high-dose radiation to VT focus non-invasively ( 2 ).…”